This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Phillips, W. P. Articles by Gerson, S. L. Search for Related Content PubMed PubMed Citation Articles by Phillips, W. P., Jr. Articles by Gerson, S. L.

O⁶-Methylguanine-DNA Methyltransferase (MGMT) Transfectants of a 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive Colon Cancer Cell Line Selectively Repopulate Heterogeneous MGMT⁺/MGMT^- Xenografts after BCNU and O⁶-Benzylguanine plus BCNU¹

Division of Hematology-Oncology [W. P. P., J. K. V. W., S. D. M., E. Z., N. H. Z., L. L., S. L. G.] and Department of Biostatistics and Epidemiology [N. H. G.], Case Western Reserve University, University Hospitals' Ireland Cancer Center, Cleveland, Ohio 44106-4937

To evaluate the role of O⁶-alkylguanine-DNA alkyltransferase (AGT) in colon tumor chloroethylnitrosourea (CENU) resistance, AGT-deficient VACO 8 cells were transfected with a vector containing or lacking the human O⁶-methylguanine-DNA methyltransferase (MGMT) cDNA. VACO 8MGMT (V8MGMT) sublines possessed high levels of AGT activity in cell culture and were > 10-fold resistant to the CENU 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). V8MGMT cells, VACO 8neo cells, and mixtures of both were grown as xenografts in nude mice. MGMT expression in VACO 8 xenografts reflected the percentage of V8MGMT cells present in the tumor inoculum. Xenografts originally containing 0–10% V8MGMT cells were sensitive to BCNU, although partial resistance was observed as the percentage of V8MGMT cells increased. Tumors containing 30–100% V8MGMT cells were completely resistant to BCNU with no regressions and no growth delays. Pretreatment with O⁶-benzylguanine (BG) depleted tumor AGT activity for at least 6 h and sensitized xenografts containing 1 and 100% V8MGMT cells to BCNU. After BCNU or BG + BCNU, xenografts growing from inoculums containing as low as 0.1% V8MGMT cells had high AGT activities similar to that found in V8MGMT xenografts, with the majority of the cells expressing MGMT. These results provide evidence that MGMT expression influences both intrinsic and acquired colon tumor CENU resistance, that selective expansion of AGT⁺ colon tumor cells commonly occurs after CENU exposure, and that BG is effective in sensitizing colon tumors to CENUs, even when only a small fraction of the cells in a heterogeneous tumor express MGMT.

¹ This work was supported in part by USPHS Grants P01CA51183, P30CA43703, RO1CA63193, RO1ES06288, and UO1CA75525.

² To whom requests for reprints should be addressed, at Division of Hematology/Oncology, Case Western Reserve University, School of Medicine (BRB), 10900 Euclid Avenue, Cleveland, OH 44106-4937.

Received 4/28/97. Accepted 9/ 5/97.

This article has been cited by other articles:

				J. N. Sarkaria, G. J. Kitange, C. D. James, R. Plummer, H. Calvert, M. Weller, and W. Wick Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma Clin. Cancer Res., May 15, 2008; 14(10): 2900 - 2908. [Abstract] [Full Text] [PDF]

				A. M. Fontes, B. M. Davis, L. P. Encell, K. Lingas, D. T. Covas, M. A. Zago, L. A. Loeb, A. E. Pegg, and S. L. Gerson Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells Mol. Cancer Ther., January 1, 2006; 5(1): 121 - 128. [Abstract] [Full Text] [PDF]

				M.-R. Lee, S.-H. Kim, H.-J. Cho, K.-Y. Lee, A. R. Moon, H. G. Jeong, J.-S. Lee, J.-W. Hyun, M.-H. Chung, and H. J. You Transcription Factors NF-YA Regulate the Induction of Human OGG1 Following DNA-alkylating Agent Methylmethane Sulfonate (MMS) Treatment J. Biol. Chem., March 12, 2004; 279(11): 9857 - 9866. [Abstract] [Full Text] [PDF]

				L. Liu, T. P. Spiro, X. Qin, S. Majka, J. Haaga, J. Schupp, J. K. V. Willson, and S. L. Gerson Differential Degradation Rates of Inactivated Alkyltransferase in Blood Mononuclear Cells and Tumors of Patients after Treatment with O6-Benzylguanine Clin. Cancer Res., August 1, 2001; 7(8): 2318 - 2324. [Abstract] [Full Text] [PDF]

				M. Kobune, Y. Xu, C. Baum, M. R. Kelley, and D. A. Williams Retrovirus-mediated Expression of the Base Excision Repair Proteins, Formamidopyrimidine DNA Glycosylase or Human Oxoguanine DNA Glycosylase, Protects Hematopoietic Cells from N,N',N''-Triethylenethiophosphoramide (thioTEPA)-induced Toxicity in Vitro and in Vivo Cancer Res., July 1, 2001; 61(13): 5116 - 5125. [Abstract] [Full Text] [PDF]

				E. L. Kreklau, N. Liu, Z. Li, K. Cornetta, and L. C. Erickson Comparison of Single- Versus Double-Bolus Treatments of O6-Benzylguanine for Depletion of O6-Methylguanine DNA Methyltransferase (MGMT) Activity in Vivo: Development of a Novel Fluorometric Oligonucleotide Assay for Measurement of Mgmt Activity J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 524 - 530. [Abstract] [Full Text]

				Z.-P. Chen, Z.-M. Wang, C. A. Carter, M. C. Alley, G. Mohr, and L. C. Panasci Both Extraneuronal Monoamine Transporter and O6-Methylguanine-DNA Methyltransferase Expression Influence the Antitumor Efficacy of 2-Chloroethyl-3-sarcosinamide- 1-nitrosourea in Human Tumor Xenografts J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 712 - 715. [Abstract] [Full Text]

				D. M. Kokkinakis, D. B. Bocangel, S. C. Schold, R. C. Moschel, and A. E. Pegg Thresholds of O6-Alkylguanine-DNA Alkyltransferase which Confer Significant Resistance of Human Glial Tumor Xenografts to Treatment with 1,3-Bis(2-chloroethyl)-1-nitrosourea or Temozolomide Clin. Cancer Res., February 1, 2001; 7(2): 421 - 428. [Abstract] [Full Text]

				E. L. Kreklau, C. Kurpad, D. A. Williams, and L. C. Erickson Prolonged Inhibition of O6-Methylguanine DNA Methyltransferase in Human Tumor Cells by O6-Benzylguanine In Vitro and In Vivo J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1269 - 1275. [Abstract] [Full Text]

				Z.-P. Chen, J. Remack, T. P. Brent, G. Mohr, and L. C. Panasci Extraneuronal Monoamine Transporter Expression and DNA Repair Vis-a-Vis 2-Chloroethyl-3-sarcosinamide-1-nitrosourea Cytotoxicity in Human Tumor Cell Lines Clin. Cancer Res., December 1, 1999; 5(12): 4186 - 4190. [Abstract] [Full Text] [PDF]

				R. Maze, C. Kurpad, A. E. Pegg, L. C. Erickson, and D. A. Williams Retroviral-Mediated Expression of the P140A, but not P140A/G156A, Mutant Form of O6-Methylguanine DNA Methyltransferase Protects Hematopoietic Cells against O6-Benzylguanine Sensitization to Chloroethylnitrosourea Treatment J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1467 - 1474. [Abstract] [Full Text]

				B. J. Glassner, G. Weeda, J. M. Allan, J. L.M. Broekhof, N. H.E. Carls, I. Donker, B. P. Engelward, R. J. Hampson, R. Hersmus, M. J. Hickman, et al. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents Mutagenesis, May 1, 1999; 14(3): 339 - 347. [Abstract] [Full Text] [PDF]

				J. R. Silber, A. Blank, M. S. Bobola, S. Ghatan, D. D. Kolstoe, and M. S. Berger O6-Methylguanine-DNA Methyltransferase-deficient Phenotype in Human Gliomas: Frequency and Time to Tumor Progression after Alkylating Agent-based Chemotherapy Clin. Cancer Res., April 1, 1999; 5(4): 807 - 814. [Abstract] [Full Text] [PDF]